vs
Side-by-side financial comparison of OCULAR THERAPEUTIX, INC (OCUL) and TRANSACT TECHNOLOGIES INC (TACT). Click either name above to swap in a different company.
OCULAR THERAPEUTIX, INC is the larger business by last-quarter revenue ($13.3M vs $11.5M, roughly 1.2× TRANSACT TECHNOLOGIES INC). On growth, TRANSACT TECHNOLOGIES INC posted the faster year-over-year revenue change (11.9% vs -22.4%). TRANSACT TECHNOLOGIES INC produced more free cash flow last quarter ($589.0K vs $-57.1M). Over the past eight quarters, TRANSACT TECHNOLOGIES INC's revenue compounded faster (3.5% CAGR vs -5.3%).
Ocular Therapeutix, Inc. is a biopharmaceutical firm specializing in developing and commercializing innovative ophthalmic therapies. Its products treat acute and chronic eye conditions including post-surgical pain, glaucoma, and dry eye, serving patients and ophthalmology providers primarily across the U.S. and select global markets.
Roper Technologies, Inc. is a holding company that owns companies in the technology sector.
OCUL vs TACT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $13.3M | $11.5M |
| Net Profit | $-64.7M | — |
| Gross Margin | 88.0% | 47.6% |
| Operating Margin | -526.5% | -10.1% |
| Net Margin | -488.0% | — |
| Revenue YoY | -22.4% | 11.9% |
| Net Profit YoY | -33.6% | — |
| EPS (diluted) | $-0.27 | $-0.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $13.3M | $11.5M | ||
| Q3 25 | $14.5M | $13.2M | ||
| Q2 25 | $13.5M | $13.8M | ||
| Q1 25 | $10.7M | $13.1M | ||
| Q4 24 | $17.1M | $10.2M | ||
| Q3 24 | $15.4M | $10.9M | ||
| Q2 24 | $16.4M | $11.6M | ||
| Q1 24 | $14.8M | $10.7M |
| Q4 25 | $-64.7M | — | ||
| Q3 25 | $-69.4M | $15.0K | ||
| Q2 25 | $-67.8M | $-143.0K | ||
| Q1 25 | $-64.1M | $19.0K | ||
| Q4 24 | $-48.4M | — | ||
| Q3 24 | $-36.5M | $-551.0K | ||
| Q2 24 | $-43.8M | $-319.0K | ||
| Q1 24 | $-64.8M | $-1.0M |
| Q4 25 | 88.0% | 47.6% | ||
| Q3 25 | 87.8% | 49.8% | ||
| Q2 25 | 85.6% | 48.2% | ||
| Q1 25 | 88.2% | 48.7% | ||
| Q4 24 | 92.8% | 44.2% | ||
| Q3 24 | 89.9% | 48.1% | ||
| Q2 24 | 90.8% | 52.7% | ||
| Q1 24 | 91.0% | 52.6% |
| Q4 25 | -526.5% | -10.1% | ||
| Q3 25 | -472.3% | 0.1% | ||
| Q2 25 | -502.6% | -1.9% | ||
| Q1 25 | -597.5% | -0.1% | ||
| Q4 24 | -296.1% | -10.3% | ||
| Q3 24 | -298.2% | -7.7% | ||
| Q2 24 | -265.1% | -3.8% | ||
| Q1 24 | -214.0% | -12.2% |
| Q4 25 | -488.0% | — | ||
| Q3 25 | -477.3% | 0.1% | ||
| Q2 25 | -503.9% | -1.0% | ||
| Q1 25 | -598.7% | 0.1% | ||
| Q4 24 | -283.3% | — | ||
| Q3 24 | -236.6% | -5.1% | ||
| Q2 24 | -266.3% | -2.8% | ||
| Q1 24 | -438.9% | -9.7% |
| Q4 25 | $-0.27 | $-0.11 | ||
| Q3 25 | $-0.38 | $0.00 | ||
| Q2 25 | $-0.39 | $-0.01 | ||
| Q1 25 | $-0.38 | $0.00 | ||
| Q4 24 | $-0.25 | $-0.80 | ||
| Q3 24 | $-0.22 | $-0.06 | ||
| Q2 24 | $-0.26 | $-0.03 | ||
| Q1 24 | $-0.49 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $737.1M | $20.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $654.3M | $31.1M |
| Total Assets | $808.1M | $44.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $737.1M | $20.4M | ||
| Q3 25 | $344.8M | $20.0M | ||
| Q2 25 | $391.1M | $17.7M | ||
| Q1 25 | $349.7M | $14.2M | ||
| Q4 24 | $392.1M | $14.4M | ||
| Q3 24 | $427.2M | $11.3M | ||
| Q2 24 | $459.7M | $11.1M | ||
| Q1 24 | $482.9M | $10.6M |
| Q4 25 | $654.3M | $31.1M | ||
| Q3 25 | $258.2M | $31.8M | ||
| Q2 25 | $305.9M | $31.3M | ||
| Q1 25 | $265.9M | $30.9M | ||
| Q4 24 | $315.3M | $30.6M | ||
| Q3 24 | $352.0M | $38.4M | ||
| Q2 24 | $377.7M | $38.5M | ||
| Q1 24 | $408.0M | $38.6M |
| Q4 25 | $808.1M | $44.8M | ||
| Q3 25 | $410.9M | $45.0M | ||
| Q2 25 | $451.3M | $44.5M | ||
| Q1 25 | $405.9M | $44.2M | ||
| Q4 24 | $457.9M | $44.0M | ||
| Q3 24 | $490.4M | $50.5M | ||
| Q2 24 | $517.1M | $50.4M | ||
| Q1 24 | $538.9M | $51.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-54.2M | $609.0K |
| Free Cash FlowOCF − Capex | $-57.1M | $589.0K |
| FCF MarginFCF / Revenue | -430.9% | 5.1% |
| Capex IntensityCapex / Revenue | 21.4% | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-216.9M | $7.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-54.2M | $609.0K | ||
| Q3 25 | $-50.7M | $3.6M | ||
| Q2 25 | $-55.2M | $3.6M | ||
| Q1 25 | $-44.7M | $-161.0K | ||
| Q4 24 | $-39.4M | $2.4M | ||
| Q3 24 | $-36.6M | $327.0K | ||
| Q2 24 | $-24.8M | $636.0K | ||
| Q1 24 | $-33.9M | $-1.5M |
| Q4 25 | $-57.1M | $589.0K | ||
| Q3 25 | $-56.7M | $3.6M | ||
| Q2 25 | $-56.5M | $3.6M | ||
| Q1 25 | $-46.6M | $-171.0K | ||
| Q4 24 | $-39.6M | $2.4M | ||
| Q3 24 | $-36.6M | $259.0K | ||
| Q2 24 | $-25.5M | $499.0K | ||
| Q1 24 | $-34.1M | $-1.6M |
| Q4 25 | -430.9% | 5.1% | ||
| Q3 25 | -390.0% | 27.1% | ||
| Q2 25 | -419.7% | 25.9% | ||
| Q1 25 | -435.6% | -1.3% | ||
| Q4 24 | -232.0% | 23.2% | ||
| Q3 24 | -237.6% | 2.4% | ||
| Q2 24 | -155.4% | 4.3% | ||
| Q1 24 | -231.1% | -14.9% |
| Q4 25 | 21.4% | 0.2% | ||
| Q3 25 | 41.2% | 0.5% | ||
| Q2 25 | 9.3% | 0.1% | ||
| Q1 25 | 18.1% | 0.1% | ||
| Q4 24 | 1.2% | 0.1% | ||
| Q3 24 | 0.6% | 0.6% | ||
| Q2 24 | 4.5% | 1.2% | ||
| Q1 24 | 1.7% | 1.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | 242.00× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -8.47× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
